Raid Aljumaily to Carcinoma, Renal Cell
This is a "connection" page, showing publications Raid Aljumaily has written about Carcinoma, Renal Cell.
Connection Strength
0.178
-
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
Score: 0.178